Impaza and Sildenafil: Comparison of Clinical Effectiveness in Patients with Erectile Dysfunction

Bulletin of Experimental Biology and Medicine

Volumn 135-136, Issue 7, 2003, Pages 150-151

  Petrov, V I ^a   Vekel'yan, A S ^a   Martyushev, A V ^b   Sergeeva, S A ^b   Smolenov, I V ^a   Epstein, O I ^b  

^a VOLGOGRAD STATE MEDICAL UNIVERSITY   (Russian Federation)

^b Materia Medica Holding R   (Russian Federation)

Author keywords

Antibodies to endothelial NO synthase; Controlled trial; Erectile dysfunction; Sildenafil; Ultralow doses

Indexed keywords

ANTIBODY; ENDOTHELIAL NITROGEN OXIDE SYNTHASE ANTIBODY; IMPAZA; SILDENAFIL; UNCLASSIFIED DRUG; VASOACTIVE AGENT;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; ERYTHEMA; HEADACHE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR; SIDE EFFECT; TACHYCARDIA; VISUAL DISORDER; VOMITING;

EID: 0345742440     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024796611758     Document Type: Article

References (4)

1. T. G. Borovskaya, O. P. Loskutova, O. I. Epstein, and M. S. Zak, Byull. Eksp. Biol. Med., Appl. 3, 52-53 (2001).
2. A. E. Benet and A. Melman, Urol. Clin. N. Am., 22, 699-709 (1995).
3. H. A. Feldman, I. Goldstein, D. G. Hatzichristou, et al., J. Urol., 151, 54-61 (1994).
4. NIH Consensus Development Panel on Impotence, JAMA, 270, 83-90 (1993).